PTC Therapeutics Reports Second Quarter ... - Investor RelationsThe Phase 3 study is expected to be conducted at 53 clinical sites ... In July 2013,
PTC submitted responses to the Day 120 Questions to the ...
ptc therapeutics recipient of parent project muscular dystrophy's... it is the recipient of Parent Project Muscular Dystrophy's (PPMD) " Path to ... The
award was presented at PPMD's Annual Connect Conference in Chicago , ...
FORWARD LOOKING STATEMENTS: This press release contains ...
PTC Therapeutics, Inc . - Email Alert SubscriptionYou may automatically receive PTC Therapeutics, Inc . financial information by
email . Please enter your preferences for email notifications below and click ...
Advanced Duchenne/ Becker Muscular Dystrophy Genetic TestingGenetic Testing for Duchenne and Becker Muscular Dystrophy . Genetic tests find
changes, called mutations, in genes that cause disease. These tests can be a ...
PTC Therapeutics Announces Expanded Access Program For -French ATU Cohort and Other Named Patient Programs Authorized - ... PTC's
EAP program is intended to make Translarna™ (ataluren) available to patients
before commercial availability in .... Close window | Back to top .
The DMD community has been waiting a long time for treatment options and this
conditional approval marks an important day for us all." ... For more information
on the company , please visit our website www.ptcbio.com.
ptc therapeutics appoints ronald c. renaud, jr. to ... - Investor RelationsHis demonstrated leadership experience in building successful biotechnology
companies, his ... plans and prospects for PTC , the timing of regulatory approvals
, the development of and potential ... Close window | Back to top .
ptc therapeutics reports inducement grants under nasdaq listing rule Six of the stock option awards have an exercise price of $24.90 per ... of the
applicable employee's new hire date and an additional 6.25% of ...
PTC Therapeutics: Advanced Duchenne/Becker Muscular Dystrophy Genetic tests find changes, called mutations, in genes that cause disease. ...
muscle cells become fragile and break down, and this leads to muscle weakness.
PTC Therapeutics: Murad HusainBoard of Directors ... In his role as Vice President of Regulatory Affairs, Mr. Murad
Husain leads the regulatory efforts to support ... He received his M.S. in
Pharmaceutical Marketing from St. John's University and his Masters and
Bachelors in ...
joint program in spinal muscular atrophy enters ... - PTC TherapeuticsSMA is a genetic neuromuscular disorder that leads to muscle weakness and
mobility impairment and is considered the leading genetic cause ...
Advanced Duchenne/Becker Muscular Dystrophy Genetic TestingGenetic Testing for Duchenne and Becker Muscular Dystrophy. Genetic tests find
changes, called mutations, in genes that cause disease. ... Background